How can we make cancer therapy kinder? 📖 Read our latest article to explore the shift from conventional to precision oncology, aiming for both more effective and kinder medicines. Join us in the quest for a future where patients could experience better quality of life during their treatment. 👇👇👇 #PrecisionOncology #HealthcareInnovation #BayerPrognosis #oncologyinspired #TeamBayer
Info
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. The Pharmaceuticals Division of Bayer focuses on prescription products for women’s healthcare, cardiology, oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.
- Website
-
https://pharma.bayer.com/imprint
Externer Link zu Bayer | Pharmaceuticals
- Branche
- Arzneimittelherstellung
- Größe
- 10.001 Beschäftigte
- Hauptsitz
- Berlin
- Spezialgebiete
- Pharmaceuticals, Healthcare, Oncology und Cardiology
Updates
-
Bayer | Pharmaceuticals hat dies direkt geteilt
We were very pleased to have hosted Bayer’s “Prostate Cancer Health Inequalities Expert Forum’’ last Tuesday 16th July, discussing key health inequality challenges in the UK with 11 leading experts in prostate cancer care. As many as 1 in 8 men are estimated to get prostate cancer within their lifetime in the UK. Despite affecting so many people and having such a significant impact nationwide, unwarranted variations in prostate cancer care across the health system are leading to stark differences in diagnoses, experiences, and outcomes for the men impacted by this disease. For example, black men are less likely to be tested for prostate cancer but are more likely to develop it. Moderated by Ursula Montgomery, Bayer UK’s Head of Communications, Public Affairs and Sustainability, along with Oxygen Strategy, the Forum explored the key factors that drive health inequalities in prostate cancer and discussed what solutions could be implemented to bring meaningful improvements in prostate cancer care in the near term. The group discussion focused on five key areas with potential solutions, including: ✔️ Diagnosis and screening – remove barriers to targeted PSA (prostate specific antigen) testing ✔️ Access to treatment – bring care closer to patients and supporting patients ‘get to care’ ✔️ Patient pathways – streamline the patient pathway and introduce ‘one stop’ shops for prostate cancer patients ✔️ Patient experience – introduce patient navigators that reflect the communities they are seeking to engage ✔️ National prostate cancer policy – develop a dedicated cancer strategy We would like to thank all the Forum participants and speakers Oliver Kemp, Prostate Cancer Research, and Professor Frank Chinegwundoh MBE, who represented key stakeholders across different specialties in prostate cancer care, ranging from urology and radiology to primary care and patient organisations. Bayer believes that addressing these health inequalities is of the utmost importance to improve care and the lives of prostate cancer patients and by collaborating with all parties in the prostate cancer care community we can find system-wide solutions together. As a next step, we will be developing a series of tangible policy recommendations for the new Government to consider implementing. We look forward to continuing to work on this important issue through 2024/25. Stay tuned for more updates! #MensHealth #HealthInequalities #AddressingHealthInequalities #ProstateCancerCare #ImprovingProstateCancerCare #BayerUKI
-
-
Get to know our data science rockstar Steffen Vogler who is working in our Radiology R&D team! As a Medical Imaging Specialist he uses AI to decipher and analyze medical images like X-rays or CT scans. Learn more about him and discover how he envisions artificial intelligence promoting healthcare equity across the globe 👇 #DataScienceRockstars #TeamBayer #InnovationInHealthcare #Radiology #AI
-
Bayer | Pharmaceuticals hat dies direkt geteilt
I had the pleasure of sitting down again with Dan Vahdat from Huma to get a first-hand view of the Huma Cloud Platform and an update on Huma’s progress within Bayer. Huma has been a bright spot in our Leaps by Bayer portfolio - they have continuously grown and delivered value in a competitive and challenging digital health market. The Huma Cloud Platform, launched last week, enables pharmaceutical companies to build and launch patient-facing digital apps in days, not years. Huma’s unique enterprise platform approach means that different teams can leverage the same software tools to configure patient apps for any disease area at any point in the medicine lifecycle, from the R&D phase through post-launch. Pharmaceutical companies need more efficient, consistent, and cost-effective means to build digital health solutions and minimize spending on duplicative efforts that can’t scale - Huma Cloud Platform can deliver this. I look forward to seeing how Dan and the Huma team continue to change the world of healthcare and life sciences by accelerating the adoption of digital & AI solutions across the board.
-
-
#News Vividion Therapeutics, Inc., a wholly owned and independently operating subsidiary of Bayer, plans to expand in San Diego with a new global Research and Development Center and corporate headquarters. #TeamBayer continues to drive growth in the biotech industry within one of the most innovative life science hubs in the United States. Learn more: http://spr.ly/6049cBiyJ #HealthForAll #HungerForNone
-
"My mom's experience with lung cancer showed me the incredible strength of patients. Now, at Bayer, I'm empowered to champion patients’ needs.” Peter Said, Patient Engagement Lead for Asia-Pacific at Bayer, shares how his mother’s lung cancer diagnosis fueled his passion for patient advocacy at Bayer. We are proud to have Peter on board, making patients' voices a priority in all we do at #TeamBayer.
-
Bayer | Pharmaceuticals hat dies direkt geteilt
#NEWS We are pleased to announce topline results from a Phase III trial in men with metastatic hormone-sensitive #ProstateCancer (mHSPC). Learn more: https://lnkd.in/ekY-krjA #TeamBayer #OncologyInspired
-
AI seems to hold a lot of different potentials. Today, we asked some of our dear #radiology colleagues from #TeamBayer, what they appreciate about #AI. Listen to Oisín Butler, Franziska Lobig, Mike McDermott and Shruti Panwalkar sharing their perspectives. Now, let us know: What do YOU appreciate about AI? #AIAppreciationDay #BayerInRadiology #SeeThePossibleCreateTheFuture
-
#Team Bayer is committed to advancing science by investing in partnerships and collaborations for research. To foster awareness and understanding of the need for safer antithrombotic therapies, we have joined industry partners in support of an educational initiative announced by the leading international society International Society on Thrombosis and Haemostasis (ISTH). We are dedicated to exploring potential new options in stroke prevention to address areas of greatest unmet need.
📣 NEWS: The ISTH announces launch of new global education initiative in factor XI/XIa inhibition 🧬 Read more here: https://lnkd.in/gZvKYxMN
ISTH announces launch of new global education initiative in factor XI/XIa inhibition
isth.org
-
Bayer | Pharmaceuticals hat dies direkt geteilt
Having the opportunity to connect with others working in the cell and gen therapy space is always a highlight in my calendar. This week I was looking forward to the #ISSCR2024 meeting in Hamburg, which is gathering more than 4000 champions from the #StemCell community. And so far I have not been disappointed. Our workshop on “Advances in in the treatment of #ParkinsonsDisease : the possibilities of cell therapy” on Wednesday was a great success ! Thank you, #VivianTabar, and #DavidPedrosa for sharing your excitement about the fascinating breakthrough data. It’s highly encouraging for both the #Parkinson patients and the cell community! In addition to that, there are so many other promising developments I learned about. Thank you, #TeamBayer, and #Bluerockers for engaging in the scientific exchange and driving innovation for patients !
-